Shares of Orexigen Therapeutics (OREX) plunged Tuesday after the Food & Drug Administration denied approval of its application for a new obesity drug. But does it justify a 72% down day on volume of 4X the company’s issued & outstanding (o/s) share count? Orexigen had developed, Contrave, a weight-loss drug, in partnership with Japan ‘s […]